Phase 1 trial of the antiangiogenic peptide ATN-161 (Ac-PHSCN-NH(2)), a beta integrin antagonist, in patients with solid tumours

To evaluate the toxicity, pharmacological and biological properties of ATN-161, a five –amino-acid peptide derived from the synergy region of fibronectin, adult patients with advanced solid tumours were enrolled in eight sequential dose cohorts (0.1–16 mg kg(−1)), receiving ATN-161 administered as a...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Cianfrocca, M E, Kimmel, K A, Gallo, J, Cardoso, T, Brown, M M, Hudes, G, Lewis, N, Weiner, L, Lam, G N, Brown, S C, Shaw, D E, Mazar, A P, Cohen, R B
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2006
Assuntos:
Clinical Study
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2361324/
https://ncbi.nlm.nih.gov/pubmed/16705310
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6603171
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados